Mehmet Nuri Turan1, Fatih Kircelli2, Mustafa Yaprak2, Ali Riza Sisman3, Ozkan Gungor2, Selen Bayraktaroglu4, Mehmet Ozkahya2, Gulay Asci2, Jurgen Floege5, Ercan Ok2. 1. Division of Nephrology, Ege University School of Medicine, 35100, Bornova, Izmir, Turkey. mnturan@mail.com. 2. Division of Nephrology, Ege University School of Medicine, 35100, Bornova, Izmir, Turkey. 3. Department of Biochemistry, Dokuz Eylul University School of Medicine, Izmir, Turkey. 4. Department of Radiology, Ege University School of Medicine, Izmir, Turkey. 5. Division of Nephrology and Clinical Immunology, RWTH University of Aachen, Aachen, Germany.
Abstract
PURPOSE: High fibroblast growth factor-23 (FGF-23) levels are associated with mortality and cardiovascular events in patients with chronic kidney disease. The aim of this cross-sectional study was to investigate the relationship between plasma FGF-23 levels and coronary artery calcification and carotid artery intima-media thickness (CA-IMT) in hemodialysis (HD) patients. METHODS: In this cross-sectional study, plasma intact FGF-23 levels were measured in 229 patients who underwent coronary artery calcification scores (CACs) determined by multi-slice computerized tomography and CA-IMT assessed by using high-resolution color Doppler ultrasonography. RESULTS:Median FGF-23 was 53.5 pg/ml (IQR 30.8-249.5). Median CACs was 98 (IQR 0-531), and the frequency of patients with severe calcification (CACs > 400) was 28.8%; 27.5% of cases had no calcification. Mean CA-IMT was 0.78 ± 0.20 mm, and the presence of carotid plaques was 51% with a mean length 2.1 mm. FGF-23 level was positively correlated with serum calcium (r = 0.337, p < 0.001), phosphate (r = 0.397, p < 0.001) and CACs (r = 0.218, p = 0.001). Neither CA-IMT nor the presence of carotid artery plaques correlated with FGF-23 levels. In adjusted ordinal regression analysis, FGF-23 level was an independent predictor for severe CACs together with age, gender, presence of diabetes, time on dialysis and CA-IMT (model r(2) = 0.44, p < 0.001). As a novel finding, the mean CACs was markedly higher in patients with FGF-23 level above median regardless of phosphate levels (p = 0.03). CONCLUSIONS: In HD patients, plasma FGF-23 level is superior to phosphate in the prediction of coronary artery calcification. However, FGF-23 is not associated with carotid artery atherosclerosis in HD patients.
RCT Entities:
PURPOSE: High fibroblast growth factor-23 (FGF-23) levels are associated with mortality and cardiovascular events in patients with chronic kidney disease. The aim of this cross-sectional study was to investigate the relationship between plasma FGF-23 levels and coronary artery calcification and carotid artery intima-media thickness (CA-IMT) in hemodialysis (HD) patients. METHODS: In this cross-sectional study, plasma intact FGF-23 levels were measured in 229 patients who underwent coronary artery calcification scores (CACs) determined by multi-slice computerized tomography and CA-IMT assessed by using high-resolution color Doppler ultrasonography. RESULTS: Median FGF-23 was 53.5 pg/ml (IQR 30.8-249.5). Median CACs was 98 (IQR 0-531), and the frequency of patients with severe calcification (CACs > 400) was 28.8%; 27.5% of cases had no calcification. Mean CA-IMT was 0.78 ± 0.20 mm, and the presence of carotid plaques was 51% with a mean length 2.1 mm. FGF-23 level was positively correlated with serum calcium (r = 0.337, p < 0.001), phosphate (r = 0.397, p < 0.001) and CACs (r = 0.218, p = 0.001). Neither CA-IMT nor the presence of carotid artery plaques correlated with FGF-23 levels. In adjusted ordinal regression analysis, FGF-23 level was an independent predictor for severe CACs together with age, gender, presence of diabetes, time on dialysis and CA-IMT (model r(2) = 0.44, p < 0.001). As a novel finding, the mean CACs was markedly higher in patients with FGF-23 level above median regardless of phosphate levels (p = 0.03). CONCLUSIONS: In HDpatients, plasma FGF-23 level is superior to phosphate in the prediction of coronary artery calcification. However, FGF-23 is not associated with carotid artery atherosclerosis in HDpatients.
Authors: Victoria Shalhoub; Edward M Shatzen; Sabrina C Ward; James Davis; Jennitte Stevens; Vivian Bi; Lisa Renshaw; Nessa Hawkins; Wei Wang; Ching Chen; Mei-Mei Tsai; Russell C Cattley; Thomas J Wronski; Xuechen Xia; Xiaodong Li; Charles Henley; Michael Eschenberg; William G Richards Journal: J Clin Invest Date: 2012-06-25 Impact factor: 14.808
Authors: Katarzyna Janda; Marcin Krzanowski; Eve Chowaniec; Beata Kuśnierz-Cabala; Paulina Dumnicka; Andrzej Kraśniak; Piotr Podolec; Władysław Sułowicz Journal: Pol Arch Med Wewn Date: 2013-03-26
Authors: Bryan Kestenbaum; Michael C Sachs; Andy N Hoofnagle; David S Siscovick; Joachim H Ix; Cassianne Robinson-Cohen; Joao A C Lima; Joseph F Polak; Marc Blondon; John Ruzinski; Denise Rock; Ian H de Boer Journal: Circ Heart Fail Date: 2014-03-25 Impact factor: 8.790
Authors: Alisson Diego Machado; Luz Marina Gómez; Dirce Maria Lobo Marchioni; Fernanda Silva Nogueira Dos Anjos; Maria Del Carmen Bisi Molina; Paulo Andrade Lotufo; Isabela Judith Martins Benseñor; Silvia Maria de Oliveira Titan Journal: Nutrients Date: 2018-03-19 Impact factor: 5.717
Authors: Markus Ketteler; Stuart M Sprague; Adrian C Covic; Anjay Rastogi; Bruce Spinowitz; Viatcheslav Rakov; Sebastian Walpen; Jürgen Floege Journal: Nephrol Dial Transplant Date: 2019-07-01 Impact factor: 5.992